联邦医疗保险低收入补贴对转移性前列腺癌患者治疗可及性、治疗选择及肿瘤学结局的影响
该研究基于监测、流行病学和最终结果-联邦医疗保险关联数据集,纳入2010至2017年确诊的66岁及以上IV期前列腺癌男性5929例,其中1766例(30%)享有低收入补贴。分析显示,低收入补贴与更倾向于选择口服而非静脉 supplementary 治疗相关,但与更少启动任何非雄激素剥夺疗法 supplementary 全身治疗及更差的总生存相关。
要点
- 低收入补贴者接受口服而非静脉 supplementary 治疗的概率差为17%(95%CI 12-22)。
- 低收入补贴者启动任何非雄激素剥夺疗法 supplementary 全身治疗的概率差为-7.9%(95%CI 4.8-11)。
- 低收入补贴者总生存期较无补贴者更差(P<.001)。
核心结论
- 低收入补贴与转移性前列腺癌男性更多使用较昂贵的口服治疗相关,但获取这些治疗仍存在障碍,作者强调需持续努力改善低收入人群的医疗可及性。
研究设计与样本
- 回顾性队列分析,使用监测、流行病学和最终结果-联邦医疗保险关联数据集,纳入2010至2017年确诊的66岁及以上IV期前列腺癌男性5929例,其中1766例(30%)享有低收入补贴。
主要发现
- 在接受了非雄激素剥夺疗法 supplementary 全身治疗的患者中,低收入补贴者接受口服而非静脉治疗的概率较无补贴者高17%(概率差17%,95%CI 12-22)。
- 低收入补贴者启动任何非雄激素剥夺疗法 supplementary 全身治疗(口服或静脉)的概率较无补贴者低7.9%(概率差-7.9%,95%CI 4.8-11)。
- 低收入补贴者的总生存期较无补贴者更差(P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients eligible for Medicare Part D low-income subsidy have lower cost-sharing for both IV and oral cancer therapies. We evaluated associations between low-income subsidy and treatment choice, treatment initiation, and overall survival in patients with metastatic prostate cancer. MATERIALS AND METHODS: We identified men aged 66 years and older diagnosed with stage IV prostate cancer between 2010 and 2017 included in the Surveillance, Epidemiology, and End Results-Medicare linked data set. Using linear probability models, we evaluated the impact of low-income subsidy on type of first supplementary treatment (oral vs IV) among patients who received nonandrogen deprivation therapy supplementary systemic therapy, and initiation of any nonandrogen deprivation therapy supplementary systemic therapy. Overall survival was estimated with Kaplan-Meier curves. RESULTS: Of the 5,929 patients included, 1,766 (30%) had low-income subsidy. On multivariable analysis, those with low-income subsidy were more likely to receive oral as opposed to IV treatments compared to patients without low-income subsidy (probability difference: 17%, 95% CI 12, 22). However, patients with low-income subsidy were less likely to initiate any nonandrogen deprivation therapy supplementary systemic therapy (oral or IV) compared to those without low-income subsidy (probability difference: 7.9%, 95% CI 4.8-11). Additionally, patients with low-income subsidy experienced worse overall survival than those without low-income subsidy (P < .001). CONCLUSIONS: While low-income subsidy was associated with increased use of more expensive oral therapies in men with metastatic prostate cancer, barriers to accessing these treatments still exist. These findings stress the importance of continued efforts to improve health care access to low-income individuals.
引用
- Joyce DD, Qin X, Sharma V, et al. The Impact of Medicare Low-income Subsidy on Access to Treatment, Treatment Choice, and Oncologic Outcomes in Patients With Metastatic Prostate Cancer. J Urol. 2023. PMID: 37341420. doi:10.1097/JU.0000000000003592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。